A carregar...
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR) signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease. Even though abiraterone and enzalutamide represent breakthroughs in the treatment of mCRPC and have demonst...
Na minha lista:
| Publicado no: | Clin Med Insights Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4798019/ https://ncbi.nlm.nih.gov/pubmed/27013902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.Ss34534 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|